Summit Therapeutics
NASDAQ: SMMTMiami, US · Founded 2020 · Delaware corporation · 394 employees on LinkedIn
Summit Therapeutics is a biopharmaceutical oncology company developing and commercializing cancer therapies, with a lead candidate, ivonescimab (SMT112/AK112), a bispecific antibody targeting PD-1 and VEGF currently in Phase 3 trials for non-small cell lung cancer. It licenses ivonescimab from Akeso for territories including the US, Canada, Europe, Japan, Latin America, the Middle East, and Africa.
Founders & leadership
MS
Manmeet SoniinChief Operating Officer and Board Member
RD
Robert DugganExecutive
MZ
Mahkam ZanganehExecutive
DR
David RoblininCOO, CMO & President of R&D2013–2020
RS
Raymond SpencerinConsultant2014–2015
DW
David WurzerNamed on SEC filing
LZ
Leopoldo ZambelettiNamed on SEC filing
VA
Valerie AndrewsNamed on SEC filing
FA
Frank ArmstrongNamed on SEC filing
GE
Glyn EdwardsNamed on SEC filing
Board
JM
Jim MellonBoard director
JH
Jeff HuberBoard director
Funding
SEC filings, press & company announcements$1.1B disclosed across 7 of 8 rounds · 2014–2026
▶$235MraisedSep 2024 · 17 investors · BiotechnologyRule 506(b)
▶$235MraisedSep 2024 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Manmeet SoniExecutive Officer, Director
- Robert DugganExecutive Officer, Director
- Jeff HuberDirector
- Mahkam ZanganehExecutive Officer, Director
- Mostafa RonaghiDirector
- Alessandra CesanoDirector
- Kenneth ClarkDirector
- Yu XiaDirector
- Robert BoothDirector
- Offering amount
- $235M
- Amount sold
- $235M
- Proceeds to insiders
- $75.5M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$200MraisedJun 2024 · 2 investors · BiotechnologyRule 506(b)
▶$200MraisedJun 2024 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Yu XiaDirector
- Ujwala MahatmeDirector
- Manmeet SoniExecutive Officer, Director
- Mostafa RonaghiDirector
- Robert DugganExecutive Officer, Director
- Mahkam ZanganehExecutive Officer, Director
- Kenneth ClarkDirector
- Alessandra CesanoDirector
- Robert BoothDirector
- Offering amount
- $200M
- Amount sold
- $200M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$50MraisedNov 2020 · 3 investors · BiotechnologyRule 506(b)
▶$50MraisedNov 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert DugganExecutive Officer
- Mahkam ZanganehDirector
- Rainer ErdtmannDirector
- Manmeet SoniDirector
- Ujwala MahatmeDirector
- Michael Paul DonaldsonExecutive Officer
- Houbiers JosExecutive Officer
- David Johnathan PowellExecutive Officer
- Camilla GrahamExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$47.4MraisedJan 2020 · 1 investors · BiotechnologyRule 506(b)
▶$47.4MraisedJan 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David RoblinExecutive Officer
- Robert W. DugganDirector
- Elaine StrackerDirector
- Glyn EdwardsExecutive Officer, Director
- Manmeet SoniDirector
- Daniel ElgerExecutive Officer
- Ventzislav StefanovDirector
- Offering amount
- $47.4M
- Amount sold
- $47.4M
- First sale
- Dec 2019
- Incorporated
- Corporation, United Kingdom
- Federal exemptions
- 06b
▶$25MraisedJan 2019 · 1 investors · BiotechnologyRule 506(b)
▶$25MraisedJan 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David WurzerDirector
- Leopoldo ZambelettiDirector
- David RoblinExecutive Officer
- Valerie AndrewsDirector
- Frank ArmstrongDirector
- Glyn EdwardsExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Jan 2019
- Incorporated
- Corporation, United Kingdom
- Federal exemptions
- 06b
▶$11.6MraisedMar 2014 · 13 investors · BiotechnologyRule 506(b)
▶$11.6MraisedMar 2014 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen DaviesDirector
- Jim MellonDirector
- Raymond SpencerExecutive Officer
- Frank ArmstrongDirector
- Glyn EdwardsExecutive Officer, Director
- Barry PriceDirector
- Offering amount
- $11.6M
- Amount sold
- $11.6M
- Sales commissions
- $698.6K
- Placement agents
- JMP Securities LLC
- First sale
- Mar 2014
- Incorporated
- Corporation, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Summit Therapeutics went on to found or lead other companies.
Competitors · 1
by search overlap
Companies competing with Summit Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Summit Therapeutics Shares Rise After Bernstein SocGen Upgradefinance.yahoo.com · Aug 2026Frequently asked questions
- What does Summit Therapeutics do?
- Summit Therapeutics is a biopharmaceutical oncology company developing and commercializing cancer therapies, with a lead candidate, ivonescimab (SMT112/AK112), a bispecific antibody targeting PD-1 and VEGF currently in Phase 3 trials for non-small cell lung cancer. It licenses ivonescimab from Akeso for territories including the US, Canada, Europe, Japan, Latin America, the Middle East, and Africa.
- How much funding has Summit Therapeutics raised?
- Summit Therapeutics has disclosed $1.1B raised across 7 of its 8 known rounds.
- Where is Summit Therapeutics headquartered?
- Summit Therapeutics is headquartered in Miami, US.